Healthcare Industry News: Vertex Pharmaceuticals
News Release - January 29, 2015
Cerulean Appoints Vice President, Clinical OperationsCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Cerulean Pharma Inc. (CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.
“Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301,” said Paul Friedman, MD, Executive Chairman of Cerulean. “She has a proven track record of planning, managing and executing complex clinical programs.”
Ms. Crowell will oversee Cerulean's clinical operations, including the Phase 2 clinical trial for CRLX101 in 3rd and 4th line renal cell carcinoma, the Phase 1 clinical trial of CRLX301 in solid tumors, and ongoing investigator-sponsored trials in non-metastatic rectal cancer and relapsed ovarian cancer.
Ms. Crowell joins Cerulean from AVEO Pharmaceuticals, Inc., where she spent approximately three years in positions of increasing responsibility in clinical operations, most recently as Vice President, Clinical Operations. Prior to AVEO, Ms. Crowell led the clinical operations efforts at Inotek Pharmaceuticals Corporation, and managed clinical operations at Vertex Pharmaceuticals. Previously, she managed clinical trials at companies including Therion Biologics and V. I. Technologies. Ms. Crowell also held process development and operations roles at Biopure Corporation and Oravax Incorporated. She started her career as a Chemist for Wyeth Ayerst Laboratories. Ms. Crowell received a B.S. in Chemistry from Randolph-Macon Woman’s College in Lynchburg, VA.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit www.ceruleanrx.com.
About Cerulean’s Dynamic Tumor Targeting™ Platform
Cerulean’s Dynamic Tumor Targeting Platform creates NDCs that are designed to provide safer and more effective cancer treatments. We believe our NDCs concentrate their anti-cancer payloads inside tumors while sparing normal tissue because they are small enough to pass through the “leaky” vasculature present in tumors but are too large to pass through the wall of healthy blood vessels. Once inside tumors, our NDCs enter tumor cells where they slowly release anti-cancer payloads from within the tumor cells.
CRLX101 is a dynamically tumor-targeted nanoparticle-drug conjugate (NDC) designed to concentrate in tumors and slowly release its anti-cancer payload, camptothecin, inside tumor cells. CRLX101 inhibits topoisomerase 1 (topo 1), which is involved in cellular replication, and hypoxia-inducible factor-1a (HIF-1a), which research suggests is a master regulator of cancer cell survival mechanisms thought to promote drug and radiation resistance. CRLX101 has shown activity in four different tumor types, both as monotherapy and in combination with other cancer treatments. CRLX101 is currently in Phase 2 clinical development and has been dosed in more than 250 patients.
CRLX301 is a dynamically tumor-targeted NDC designed to concentrate in tumors and slowly release its anti-cancer payload, docetaxel, inside tumor cells. In preclinical studies, CRLX301 delivers up to 10 times more docetaxel into tumors, compared to an equivalent milligram dose of commercially available docetaxel and was superior to docetaxel in seven of seven animal models, with a statistically significant survival benefit seen in five of those seven models. In addition, preclinical data show that CRLX301 had lower toxicity than has been reported with docetaxel in similar preclinical studies. CRLX301 is currently in Phase 1 clinical development.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, statements about our estimated research and development expenses and sufficiency of cash to fund specified use of cash and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.
Avastin® is a trademark of Genentech Inc.
Source: Cerulean Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.